PROCEPT BioRobotics Co. (NASDAQ:PRCT) Shares Sold by Champlain Investment Partners LLC

Champlain Investment Partners LLC cut its holdings in PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 52.4% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 650,293 shares of the company's stock after selling 714,986 shares during the period. Champlain Investment Partners LLC owned 1.25% of PROCEPT BioRobotics worth $52,101,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. increased its stake in PROCEPT BioRobotics by 13.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 402,565 shares of the company's stock worth $32,254,000 after acquiring an additional 46,665 shares during the last quarter. Intech Investment Management LLC bought a new stake in PROCEPT BioRobotics in the 3rd quarter worth approximately $979,000. Advisors Asset Management Inc. increased its stake in PROCEPT BioRobotics by 28.8% in the 3rd quarter. Advisors Asset Management Inc. now owns 12,350 shares of the company's stock worth $989,000 after acquiring an additional 2,758 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new stake in PROCEPT BioRobotics in the 3rd quarter worth approximately $1,371,000. Finally, Segall Bryant & Hamill LLC bought a new stake in PROCEPT BioRobotics in the 3rd quarter worth approximately $8,076,000. 89.46% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at PROCEPT BioRobotics

In other news, CEO Reza Zadno sold 288,461 shares of the stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $91.00, for a total transaction of $26,249,951.00. Following the transaction, the chief executive officer now owns 258,445 shares of the company's stock, valued at approximately $23,518,495. This represents a 52.74 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Kevin Waters sold 25,000 shares of the stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $72.47, for a total value of $1,811,750.00. Following the transaction, the chief financial officer now directly owns 96,096 shares in the company, valued at $6,964,077.12. The trade was a 20.64 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 561,773 shares of company stock valued at $49,073,125 in the last quarter. 17.40% of the stock is owned by insiders.

Analyst Ratings Changes

PRCT has been the topic of a number of research reports. TD Cowen lifted their price objective on PROCEPT BioRobotics from $75.00 to $99.00 and gave the stock a "buy" rating in a research note on Monday, September 16th. Truist Financial reissued a "buy" rating and set a $105.00 target price (up previously from $95.00) on shares of PROCEPT BioRobotics in a research report on Wednesday, October 30th. Wells Fargo & Company boosted their target price on PROCEPT BioRobotics from $67.00 to $69.00 and gave the company an "overweight" rating in a research report on Friday, August 2nd. Piper Sandler reissued an "overweight" rating and set a $75.00 target price on shares of PROCEPT BioRobotics in a research report on Tuesday, October 8th. Finally, Bank of America boosted their target price on PROCEPT BioRobotics from $80.00 to $94.00 and gave the company a "buy" rating in a research report on Thursday, August 22nd. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, PROCEPT BioRobotics presently has an average rating of "Moderate Buy" and a consensus price target of $89.50.

PROCEPT BioRobotics Trading Down 0.9 %

PROCEPT BioRobotics stock traded down $0.85 during mid-day trading on Friday, hitting $93.60. The company's stock had a trading volume of 361,211 shares, compared to its average volume of 1,244,742. The company has a 50 day moving average of $82.41 and a 200-day moving average of $72.53. The stock has a market cap of $4.88 billion, a PE ratio of -48.00 and a beta of 1.01. The company has a debt-to-equity ratio of 0.21, a quick ratio of 5.07 and a current ratio of 6.02. PROCEPT BioRobotics Co. has a one year low of $33.45 and a one year high of $103.81.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last announced its quarterly earnings data on Monday, October 28th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.09. The company had revenue of $58.40 million for the quarter, compared to the consensus estimate of $53.30 million. PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. PROCEPT BioRobotics's quarterly revenue was up 66.4% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.51) EPS. On average, research analysts anticipate that PROCEPT BioRobotics Co. will post -1.74 EPS for the current year.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).